How many investments has Latterell Venture Partners made?

Latterell Venture Partners has 31 tracked investments, 13 of which have exited.

What stage does Latterell Venture Partners invest at?

Latterell Venture Partners invests at the Seed, Series A stages.

What is Latterell Venture Partners's typical check size?

Latterell Venture Partners typically writes checks of $50K – $10M.

What sectors does Latterell Venture Partners focus on?

Latterell Venture Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Latterell Venture Partners located?

Latterell Venture Partners is headquartered in San Ramon, US.

Does Latterell Venture Partners lead rounds?

Yes, Latterell Venture Partners leads investment rounds.

Who does Latterell Venture Partners co-invest with?

Latterell Venture Partners most often shares deals with The Vertical Group, Frazier Life Sciences, Lightstone Ventures, among 18 tracked co-investors.

Latterell Venture Partners

Venture capital

San Ramon · Seed–Series A · 6 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Latterell Venture Partners

25 people in our graph share verified history with the Latterell Venture Partners team — schools, employers, funds. One of them is your warm intro.

Paul LaVioletteunlockedknows Steve Salmon · together at CR Bard (overlapped)

×6knows the team · via CR Bard

×5knows the team · via Pulmonx Corp.

✨ Fox Verdict

Investment thesis

Latterell Venture Partners backs early-stage healthcare companies developing innovative technologies addressing large markets, led by passionate entrepreneurs. The firm combines venture capital, entrepreneurial, technical, clinical, and collaborative expertise to help founders build successful startups. LVP aims to assemble a portfolio of leading biotechnology and medical device companies that generate strong returns for its limited partners while delivering major new disease treatments benefiting patients worldwide.

Invests inBiotech Digital Health Healthtech Medical Devices United States

Source: firm website, verified Aug 3, 2026.

Stage

Seed–Series A

Check

$50K – $10M

San Ramon, California, US

Leads rounds

Leads

Instruments

Equity

Founded

2001

AUM

$300M

Tracked investments

IPOs

Acquisitions

Team · 6 people

from the firm's website & public directories

Pat Latterell· Founder

Pat Latterell founded Latterell Venture Partners (LVP) in 2001 after spending 14 years as a General Partner at Venrock Associates. He previously was a General Partner at Rothschild Ventures and an executive at Syntex Pharmaceuticals, where he helped set up its venture capital program, and earlier conducted molecular biology and biomedical engineering research at MIT. His career has focused on startup and early-stage healthcare investments, contributing to the formation of more than three dozen medical companies. He holds an MBA from Stanford Business School and SB degrees in biological sciences and economics from MIT.

p•••@lvpcapital.comreveal

Bob Curry

b•••@lvpcapital.comreveal

Ken Widder· San Jose, California, United Statesin

k•••@lvpcapital.comreveal

Peter Fitzgerald

Jim Woody· General Partner· Palo Alto, CA

Jim Woody has over 30 years of pharmaceutical research and management experience. He was founding CEO of OncoMed Pharmaceuticals and previously served as President and General Manager of Roche Bioscience and as Chief Scientific Officer and SVP of R&D at Centocor, where he helped develop Remicade and ReoPro. Earlier, he was a Navy Medical Officer who helped found the National Marrow Donor Program; he holds an M.D. from Loma Linda University and a Ph.D. in Immunology from the University of London.

j•••@lvpcapital.comreveal

Steve Salmon· General Partner· Napa, California, United Statesin

Steve Salmon has over 20 years of medical device product development and management experience. He has held executive and R&D leadership roles at both large and startup medical device companies, including Engineering Manager at CVIS (acquired by Boston Scientific), VP R&D at Boston Scientific, Co-Founder and VP Operations of Integrated Vascular Systems (acquired by Abbott), and Co-Founder of Ensure Medical (acquired by JNJ). He has authored or co-authored 18 U.S. patents and holds a B.S. in Chemical Engineering from the University of Maine.

s•••@lvpcapital.comreveal

What they invest in

from 8 of 31 portfolio companies

Biotech ×7Healthtech ×5Medical Devices ×3Hardware ×1

HQs:United States×7

Investments · 31 tracked

founders shown can be your intro path

By year:2018 · 1 2005 · 12 dated

Pulmonx Corp.pulmonx.com in 𝕏NASDAQ: LUNG

Pulmonx develops the Zephyr Valve, a bronchoscopic device used to treat patients with severe COPD/emphysema without surgery.

BiotechHealthtechMedical DevicesSan Jose, US

LAUREN CRISTINA(Executive Officer)inSri Radhakrishnan(Chief Technology Officer)inMICHAEL BAKER(Executive Officer, Director)inGlendon E. French(Chief Executive Officer and Director)Derrick Sung(Chief Operating Officer and Chief Financial Officer)inGeoffrey Beran Rose(Chief Commercial Officer)

Co-investorsBand of Angels HealthCap Kaiser Permanente Ventures Ally Bridge Group Montreux Equity Partners

Aptinyxaptinyx.com

BiotechEvanston, US

Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)

BoardLiam Ratcliffe(Director)Terry P. Gould(Director)

Co-investorsBain Capital Life Sciences Frazier Life Sciences Longitude Capital OUP (Osage University Partners)Agent Capital HBM Healthcare Investments +2 more

Evoke Websiteevokepharma.com

Evoke Pharma develops treatments for gastrointestinal disorders, focusing on advancing and commercializing GIMOTI, a nasal spray formulation for diabetic gastroparesis.

BiotechHealthtechMedical Devices

Cam L. Garner(Co-founder and Chairman)Matthew J. D'Onofrio(Co-founder & Chief Executive Officer)

Inova Labsinovalabs.comacquired by ResMed

Developed lightweight portable oxygen concentrators; acquired by ResMed.

HealthtechAustin, US

John B. Rush(Executive Officer, Director)Daniel Jensen(Executive Officer)

Board Geoff Pardo(Director)inStephen M. Salmon(Director)Richard Lin(Director)Roderick A. Young(Director)

Co-investorsGilde Healthcare

IntegenX Websiteintegenx.comacquired by Thermo Fisher Scientific

Commercializing rapid DNA analysis technology for forensics; acquired by Thermo Fisher Scientific in 2018.

BiotechHardwareMedical Devices

Co-investorsQuestMark Partners

Naurexnaurex.com

Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.

BiotechEvanston, US

Joseph R. Moskal(Executive Officer)inAmin Khan(Executive Officer)inJames Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)

Co-investorsCota Capital EcoR1 Capital Sofinnova Ventures Adams Street Partners

OncoMed Websiteoncomed.com inacquired by Mereo BioPharma

Mereo BioPharma is a rare disease drug developer that funds and advances novel therapeutic candidates not progressed by their originating pharmaceutical or biotech companies, with lead programs in osteogenesis imperfecta and Alpha-1 Antitrypsin Deficiency-associated Lung Disease.

BiotechHealthtech

Co-investorsThe Vertical Group

Viracta Websiteviracta.com

Viracta Therapeutics was a precision oncology company.

BiotechHealthtechCardiff, US

Co-investorsAisling Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

CalistogaCellective TherapeuticsEnsure MedicalEvokeForteBioForteBio WebsiteMeritageMeritage PharmaOncoMedOncoMed PharmaceuticalsPathwayPathway WebsitePerceptiMedPetrolix WebsiteProteinSimpleProteinSimple WebsiteProteolixRevascular TherapeuticsTetraLogicTetraLogic WebsiteTranscendTranscend WebsiteViracta

Exits · 13

1 IPOs · 12 acquisitions

Pulmonx Corp.NASDAQ: LUNGCalistogaacq. by GileadCellective Therapeuticsacq. by MedImmuneEnsure Medicalacq. by Johnson & JohnsonForteBioacq. by PallInova Labsacq. by ResMedIntegenX Websiteacq. by Thermo Fisher ScientificMeritageacq. by ShireOncoMed Websiteacq. by Mereo BioPharmaPathwayacq. by MedradProteolixacq. by Onyx PharmaceuticalsRevascular Therapeuticsacq. by Boston ScientificTranscendacq. by Alcon

Portfolio news

latest coverage across their companies

Brokerages Set Pulmonx Corporation (NASDAQ:LUNG) PT at $5.58 - Defense World

Pulmonx Corp. · defenseworld.net · Jul 19, 2026

Frequently asked questions

How many investments has Latterell Venture Partners made?: Latterell Venture Partners has 31 tracked investments, 13 of which have exited.
What stage does Latterell Venture Partners invest at?: Latterell Venture Partners invests at the Seed, Series A stages.
What is Latterell Venture Partners's typical check size?: Latterell Venture Partners typically writes checks of $50K – $10M.
What sectors does Latterell Venture Partners focus on?: Latterell Venture Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Latterell Venture Partners located?: Latterell Venture Partners is headquartered in San Ramon, US.
Does Latterell Venture Partners lead rounds?: Yes, Latterell Venture Partners leads investment rounds.
Who does Latterell Venture Partners co-invest with?: Latterell Venture Partners most often shares deals with The Vertical Group, Frazier Life Sciences, Lightstone Ventures, among 18 tracked co-investors.

Similar investors

US Venture Partners

US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.

$500K – $10M

Wavemaker Three-Sixty Health

Wavemaker 360 is a healthcare-focused venture capital firm that backs entrepreneurs building disruptive companies transforming the healthcare industry. Its limited partners are largely individuals with significant healthcare industry experience.

$500K – $2M

HealthQuad

HealthQuad is a healthcare-focused investment firm that partners with entrepreneurs building category-defining healthcare businesses, leveraging its healthcare network and clinical/operating expertise.

Next Ventures

Next Ventures is an investment firm that backs founders building solutions to improve health care access and enhance human capability.

$500K – $3M

CABHI Ventures

CABHI (Centre for Aging + Brain Health Innovation) is a pan-Canadian organization that funds and supports researchers, innovators, and startups working on brain health and aging solutions, and helps healthcare and community organizations adopt them.